Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by a tissue test (biopsy) to have an advanced solid tumour cancer that cannot be surgically removed, has spread to other parts of the body, or has come back after treatment
• People whose tumour has been tested and found to have a specific genetic feature called dMMR/MSI-H (a type of DNA repair problem), or whose tumour has not yet been tested for this feature (testing may be arranged through the trial's central laboratory)
• People who are able to provide a stored or freshly collected tumour tissue sample (a fresh sample is preferred)
• People whose next planned treatment is the study drug GSK5460025
• People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities independently) (confirm with trial site)
• People who are expected to live for at least 3 more months
• People whose kidneys, liver, and other organs are functioning at a level that meets the trial's requirements (confirm with trial site for specific thresholds)

For Part 1 of the trial only, people who have already tried all standard available cancer treatments for their advanced solid tumour may be considered.

For Part 2 of the trial only:

• People who have been confirmed by tissue test to have advanced colorectal cancer (bowel cancer) or endometrial cancer (womb cancer) that cannot be surgically removed, has spread, or has come back
• People who have already received at least 1 but no more than 3 rounds of systemic cancer treatment for their advanced disease, including at least one treatment involving immune checkpoint inhibitors (a type of immunotherapy)
• People who have at least one area of cancer that can be measured on scans during the screening period, according to standard measurement guidelines

Who may not be able to join:

• People who have not yet recovered from side effects caused by previous cancer treatments (side effects need to have returned to a mild or baseline level)
• People who have previously been treated with a WRN inhibitor or a Nucleotide Excision Repair Targeting (NERT) agent — a specific type of experimental cancer drug (confirm with trial site if unsure)
• People who are unable to swallow and keep down tablets or capsules taken by mouth
• People who have cancer that has spread to the brain or central nervous system and has not been treated or is continuing to grow
• People who have, or have had within the last 2 years, a second separate cancer that is active or required treatment — with some exceptions for certain minor skin cancers or non-spreading cancers that have been fully removed
• People who have a digestive system condition that could significantly affect how the study drug is absorbed by the body
• People who have liver cirrhosis or an unstable liver or bile duct condition
• People who have a known allergy or sensitivity to the study drug or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.